Trial Profile
A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and characterized by eosinophil levels (Study 208657)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms MATINEE
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 03 Sep 2023 This trial has been completed in Poland according to European Clinical Trials Database record.
- 25 Aug 2023 Planned End Date changed from 31 May 2024 to 19 Aug 2024.
- 25 Aug 2023 Planned primary completion date changed from 31 May 2024 to 19 Aug 2024.